To learn more about these compounds, choose areas of interest in the table below (select all that apply).
total trials found
PD-L1=programmed cell death ligand-1; FGFR=fibroblast growth factor receptor; PARP=poly ADP-ribose polymerase; mTORC=mammalian target of rapamycin complex; CTLA-4=cytotoxic T-lymphocyte-associated antigen-4; NSCLC=non-small cell lung cancer; EGFR=epidermal growth factor receptor; TKI=tyrosine kinase inhibitor; HNSCC=head and neck squamous cell carcinoma; STAT3=signal transducer and activator of transcription 3; GE=gastroesophageal; GITR=glucocorticoid-induced TNF receptor; A2AR=adenosine A2a receptor; TLR7/8=toll-like receptor 7/8.
1. Melero I, Grimaldi AM, Perez-Gracia JL, Ascierto PA. Clinical development of immunostimulatory monoclonal antibodies and opportunities for combination. Clin Cancer Res. 2013;19(5):997-1008. 2. AstraZeneca. Clinical trials appendix Q1 2017 results update. https://www.astrazeneca.com/content/dam/az/PDF/2017/QR1/Q1_2017_Results_Clinical_Trial_Appendix.pdf. Accessed May 10, 2017.